ExodusPoint Capital Management LP Buys New Holdings in Denali Therapeutics Inc. $DNLI

ExodusPoint Capital Management LP bought a new stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,023,253 shares of the company’s stock, valued at approximately $16,894,000. ExodusPoint Capital Management LP owned 0.70% of Denali Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Headlands Technologies LLC purchased a new stake in Denali Therapeutics in the 2nd quarter worth approximately $26,000. Johnson Financial Group Inc. purchased a new stake in Denali Therapeutics in the 3rd quarter worth approximately $29,000. State of Wyoming purchased a new stake in Denali Therapeutics in the 2nd quarter worth approximately $29,000. Aster Capital Management DIFC Ltd purchased a new stake in Denali Therapeutics in the 4th quarter worth approximately $57,000. Finally, Quarry LP purchased a new stake in Denali Therapeutics in the 3rd quarter worth approximately $64,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Down 1.3%

Shares of NASDAQ:DNLI opened at $21.93 on Wednesday. Denali Therapeutics Inc. has a 52-week low of $12.58 and a 52-week high of $23.77. The firm has a market capitalization of $3.48 billion, a P/E ratio of -7.61 and a beta of 1.03. The stock has a 50 day moving average price of $19.86 and a 200-day moving average price of $19.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.28 and a current ratio of 9.28.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same period in the prior year, the business posted ($0.78) earnings per share. As a group, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DNLI has been the subject of several research analyst reports. Leerink Partners dropped their price objective on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Morgan Stanley dropped their price objective on Denali Therapeutics from $40.00 to $35.00 and set an “overweight” rating for the company in a report on Friday, May 22nd. Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 price objective on shares of Denali Therapeutics in a report on Monday, March 2nd. UBS Group reiterated a “buy” rating on shares of Denali Therapeutics in a report on Tuesday. Finally, Wolfe Research initiated coverage on Denali Therapeutics in a report on Monday, February 23rd. They issued a “peer perform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.25.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.